Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068267954> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2068267954 endingPage "524" @default.
- W2068267954 startingPage "524" @default.
- W2068267954 abstract "Colorectal cancer is the fourth most common malignant disease in Korea. Until recently, fluorouracil was the only effective chemotherapeutic agent for colorectal cancer. But during the past decades, the Food and Drug Administration (FDA) has approved four new drugs for advanced colorectal cancer. Two of them (irinotecan and oxaliplatin) are cytotoxic drugs, whereas the other two (bevacizumab and cetuximab) are monoclonal antibodies against molecular targets. Bevacizumab, a humanized antibody directed against the vascular endothelial growth factor, has been examined in combination with chemotherapeutic agents in several clinical trials in patients with advanced colorectal cancer. According to the phase III randomized controlled clinical trial, the addition of bevacizumab to IFL (irinotecan, 5-FU, leucovorin) led to an impressive, statistically significant increase in the rate of response and prolongation in median overall survival. Recently, a statistically significant prolongation in median survival was also reported with the addition of bevacizumab to FOLFOX4 (oxaliplain, 5-FU, leucovorin) regimen in patients with advanced colorectal cancer. Cetuximab is a monoclonal antibody against the epidermal growth factor receptor. It appears to be synergistic with irinotecan, even in irinotecan- refractory tumors. The most common side effect of cetuximab is acne-like rash, and interestingly, the development and severity of it have been correlated with an increased likelihood of an objective response. In the future, additional research will be required to define the optimal selection and scheduling of available cytotoxic and biologic treatment in individually tailored therapeutic strategies." @default.
- W2068267954 created "2016-06-24" @default.
- W2068267954 creator A5023357354 @default.
- W2068267954 creator A5082317667 @default.
- W2068267954 date "2007-01-01" @default.
- W2068267954 modified "2023-10-16" @default.
- W2068267954 title "The Role of Targeted Therapy in the Treatment of Metastatic Colorectal Cancer" @default.
- W2068267954 cites W1996584245 @default.
- W2068267954 cites W1998085563 @default.
- W2068267954 cites W2010397777 @default.
- W2068267954 cites W2012852444 @default.
- W2068267954 cites W2015136221 @default.
- W2068267954 cites W2033597946 @default.
- W2068267954 cites W2042411798 @default.
- W2068267954 cites W2052066839 @default.
- W2068267954 cites W2064047613 @default.
- W2068267954 cites W2069826874 @default.
- W2068267954 cites W2074937425 @default.
- W2068267954 cites W2090359261 @default.
- W2068267954 cites W2121368761 @default.
- W2068267954 cites W2134920919 @default.
- W2068267954 cites W2142564546 @default.
- W2068267954 cites W2145224595 @default.
- W2068267954 cites W2151979638 @default.
- W2068267954 cites W2156575195 @default.
- W2068267954 cites W2157769714 @default.
- W2068267954 cites W2168377135 @default.
- W2068267954 cites W2263132210 @default.
- W2068267954 cites W2314927739 @default.
- W2068267954 cites W2332173547 @default.
- W2068267954 doi "https://doi.org/10.3393/jksc.2007.23.6.524" @default.
- W2068267954 hasPublicationYear "2007" @default.
- W2068267954 type Work @default.
- W2068267954 sameAs 2068267954 @default.
- W2068267954 citedByCount "1" @default.
- W2068267954 crossrefType "journal-article" @default.
- W2068267954 hasAuthorship W2068267954A5023357354 @default.
- W2068267954 hasAuthorship W2068267954A5082317667 @default.
- W2068267954 hasBestOaLocation W20682679541 @default.
- W2068267954 hasConcept C121608353 @default.
- W2068267954 hasConcept C126322002 @default.
- W2068267954 hasConcept C143998085 @default.
- W2068267954 hasConcept C2781230642 @default.
- W2068267954 hasConcept C526805850 @default.
- W2068267954 hasConcept C71924100 @default.
- W2068267954 hasConceptScore W2068267954C121608353 @default.
- W2068267954 hasConceptScore W2068267954C126322002 @default.
- W2068267954 hasConceptScore W2068267954C143998085 @default.
- W2068267954 hasConceptScore W2068267954C2781230642 @default.
- W2068267954 hasConceptScore W2068267954C526805850 @default.
- W2068267954 hasConceptScore W2068267954C71924100 @default.
- W2068267954 hasIssue "6" @default.
- W2068267954 hasLocation W20682679541 @default.
- W2068267954 hasOpenAccess W2068267954 @default.
- W2068267954 hasPrimaryLocation W20682679541 @default.
- W2068267954 hasRelatedWork W1997977112 @default.
- W2068267954 hasRelatedWork W2055244682 @default.
- W2068267954 hasRelatedWork W2103502575 @default.
- W2068267954 hasRelatedWork W2402935083 @default.
- W2068267954 hasRelatedWork W2589291983 @default.
- W2068267954 hasRelatedWork W2784706285 @default.
- W2068267954 hasRelatedWork W3030554690 @default.
- W2068267954 hasRelatedWork W3030758306 @default.
- W2068267954 hasRelatedWork W76115934 @default.
- W2068267954 hasRelatedWork W2417378094 @default.
- W2068267954 hasVolume "23" @default.
- W2068267954 isParatext "false" @default.
- W2068267954 isRetracted "false" @default.
- W2068267954 magId "2068267954" @default.
- W2068267954 workType "article" @default.